Stefan Blochlinger

Showing 1-2 of 2 articles

Author Thomas Pilgrim

Coronary interventions

Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction

Pilgrim T, Piccolo R, Heg D, Roffi M, Tüller D, Vuilliomenet A, Muller O, Cook S, Weilenmann D, Kaiser C, Jamshidi P, Khattab A, Taniwaki M, Rigamonti F, Nietlispach F, Blochlinger S, Wenaweser P, Jüni P, Windecker S

December 9, 2016 | 10.4244/EIJY15M12_09

Author Masanori Taniwaki

Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

Taniwaki M, Stefanini GG, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernández-Antolín R, Baumbach A, Blochlinger S, Jüni P, Mainar V, Sabaté M, Windecker S

August 20, 2015 | 10.4244/EIJY14M07_12

1

Latest news

Antiplatelet strategies for complex PCI, are all DES equal at 10-year follow-up? cost-effectiveness of TAVR…find all the answers in the new issue

(Intravascular lithotripsy (3.5 mm Shockwave; left), followed by balloon dilatation (4.0 mm NC; right))

December 6, 2019

Discover 5 new trials: GALILEO, CONDI-2/ERIC-PCI, EVOLUTE II-5 years, SCOPE and Excel 5 years

(The Trials book is supported by Biotronik)

December 13, 2019

New this week: A Dose-response Meta Analysis, stroke after MitraClip and more

December 10, 2019

The challenge of innovation for the (interventional?) cardiology world

December 6, 2019

Guidance Papers

Guidelines, consensus & position papers

2019 – A leap year for valvular heart disease

(Course directors PCR London Valves 2019)

November 15, 2019

Last week's JAA's: EXTREME Study, Stent Optimization and more

December 3, 2019

Coronary

Valvular disease

Heart failure

Peripheral

Hypertension

Stroke